Entities

Founder and technology operator with three startup exits; Cambridge and INSEAD graduate and non-executive director at Techspert.io.

Previously headed hedge-fund investments at Northwater Capital Management and served as chief investment officer at DGAM and the Carlyle Liquid Markets Group.

Finance and operations professional with more than 25 years at RBC across banking, finance, corporate credit and foreign exchange; CFA charterholder.

Toronto-based venture investment firm backing early-stage technologies for mental health and wellbeing. Its neuroscience and central-nervous-system focus spans novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices and wearables, emphasizing evidence-backed treatments, prevention and early intervention. Its published portfolios distinguish Fund I and Fund II; these existing vehicles are not presented as newly launched funds in 2024.

Nemariam Mesfin is chief financial officer of Asset Management Ventures, LLC, listed in its March 2026 SEC filing with an appointment beginning September2022. Cedars-Sinai’s own Technology Ventures report separately lists Mesfin as fractional CFO of Cedars-Sinai Health Ventures. Neither source establishes a full-time employment arrangement at AMV.

Richard T. “Rich” Simoni is a managing member of Asset Management Ventures, LLC, confirmed in its March 2026 SEC filing. Its archived own team directory identifies him as Rich Simoni, Partner, and its own current LinkedIn page lists Richard Simoni among employees.

Asset Management Ventures (AMV) is a California venture capital firm investing in early-stage digital health, life sciences and technology companies. Its own published portfolio includes Reify Health, Evidation Health, Lark, Twist Bioscience, SubjectWell and Freenome, spanning healthcare data, AI-enabled health services and biotechnology. The firm traces its history to Pitch Johnson’s founding in 1965. Its current legal adviser is Asset Management Ventures, LLC, an SEC exempt reporting adviser; the March 2026 filing identifies David “Skip” Fleshman, Richard Simoni and Louis “Lou” Lange as managing members and Nemariam Mesfin as chief financial officer. Its current regulatory principal office is in Menlo Park, while its own LinkedIn page retains a historical Palo Alto address. Four private fund vehicles are disclosed in its regulatory filing. Reported asset values and fundraising targets are distinct from actual subscribed capital. The official domain is assetman.com; the website is currently unavailable, so current regulatory records and the firm’s own LinkedIn page supplement archived original branding and biographies.

Michael Weintraub is published by Atropos Health as board member. Co-Founder and Managing Partner, Ardan Equity. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Matthew Bettonville is published by Atropos Health as board member. Investor at Yosemite. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Gerald McDougall is published by Atropos Health as life sciences advisory board member. Atropos Health Life Sciences Advisor. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Barbara Salami is published by Atropos Health as life sciences advisory board member. Fmr Vice President, Moderna. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Brian Hasselfeld is published by Atropos Health as clinical advisory board member. Senior Medical Director, Digital Health Innovation, Johns Hopkins Medicine. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

David McSwain is published by Atropos Health as clinical advisory board member. System Chief Medical Informatics Officer & Professor of Pediatric Critical Care Medicine, UNC Health. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Elmer Polite is published by Atropos Health as clinical advisory board member. Eastern Division Interim President & Chief Financial Officer, LifePoint Health. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Tip Kim is published by Atropos Health as clinical advisory board member. Chief Market Development Officer, Stanford Health Care. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

David Klonoff is published by Atropos Health as clinical advisory board member. Medical Director of the Dorothy L. & James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center Sutter Health & a Clinical Professor of Medicine, UCSF. President of DTS. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Rasu Shrestha is published by Atropos Health as clinical advisory board member. Chief Innovation and Commercialization Officer, Executive Vice President, Advocate Health. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Robert Harrington is published by Atropos Health as clinical advisory board member. Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Neera Ahuja is published by Atropos Health as clinical advisory board chair. Clinical Advisory Board Chair Division Chief – Hospital Medicine, Medical Director-Pharmacy, Medical Director- General Inpatient Medicine, Clinical Professor Stanford University School of Medicine. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Cecily Harris is published by Atropos Health as legal. Legal. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Neil Sanghavi is published by Atropos Health as president, products & solutions. President, Products & Solutions. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Drew Turitz is published by Atropos Health as chief financial officer. Chief Financial Officer. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Kevin Smith is published by Atropos Health as chief growth officer. Chief Growth Officer. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Cory Wiegert is published by Atropos Health as chief operating officer. Chief Operating Officer. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Saurabh Gombar is published by Atropos Health as chief medical officer and co-founder. Chief Medical Officer & co-Founder of Atropos Health. Adjunct professor of medicine at Stanford School of Medicine Hear from Dr. Gombar. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Brigham Hyde is published by Atropos Health as chief executive officer and co-founder. Chief Executive Officer & co-Founder of Atropos Health Hear from Dr. Hyde. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket. Audere Capital’s own directory names Dr.Brigham Hyde a venture partner. Its career biography describes founding/leadership experience at ConcertAI and SymphonyAI. Current Atropos Health CEO/cofounder and board membership remain separate existing roles; no individual cash investment is inferred.

Atropos Health is a Palo Alto healthcare AI company developing tools that turn real-world clinical data into evidence for medical decisions and research. It grew from Stanford’s Green Button and clinical informatics consult research; its current company timeline and December2020 launch announcement identify a 2020 launch, while a 2024 financing release describes a 2019 founding. Its founders are Brigham Hyde, Nigam Shah and Saurabh Gombar. Products include GENEVA OS, Green Button, ChatRWD, Alexandria, Forge and the Atropos Evidence Agent, supporting evidence generation, precision medicine and healthcare/life-sciences research. The company’s current site publishes nine unique founders/leadership members, eight clinical advisors, four life-sciences advisors and five board members, with some overlapping founder roles. Issuer announcements verify an undisclosed seed financing completed in fall2020, a USD14M SeriesA in August2022, an undisclosed strategic financing in September2023 and a USD33M SeriesB in May2024. Valtruis led the SeriesB. Customer and clinical-data partnerships are distinguished from equity investments. Atropos Health is a separate entity from the defense and cargo-drone company Atropos Group; their domains, teams and investment histories remain separate.

Nigam Shah is published by Atropos Health as co-founder. Co-Founder of Atropos Health & Chief Data Scientist at Stanford Health Care Hear from Dr. Shah. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Luis Martinez is Venture Principal at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Nina Shelat is Director of Government Ventures at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Morgan Odell is Director of Ventures at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Jamie Serio is Vice President, Ventures at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Nick Spiller is Managing Director, All Access Fund at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Bryan Chambers is Co-Founder & President at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Joshua Baer is Founder & CEO at Capital Factory, according to its current official team directory reviewed October 7, 2026.

AirMDR provides AI-powered managed detection and response for lean security teams, small and medium-sized enterprises, and managed security service providers. Its agentic security operations platform connects to customers’ security tools to monitor threats, deploy detections, triage alerts, investigate incidents and support response and containment. AI analysts automate investigation and document the evidence, reasoning and recommended actions; a 24-hour team of human security experts reviews findings, escalates cases and provides oversight. AirMDR also offers its AI SOC platform to enterprises and MSSPs, and publishes SOC Grader to assess the quality of investigation reports. The company aims to make comprehensive security operations available without requiring customers to staff a large internal SOC.

Arize AI develops observability and evaluation infrastructure for AI applications, including large language models, agents, multimodal systems and traditional machine learning. Its managed Arize AX platform and open-source Phoenix library let engineering teams trace application behavior, run evaluations, inspect failures, compare experiments and monitor production performance. These tools help teams diagnose model drift, hallucinations and unreliable agent behavior, then improve prompts, models and workflows using evidence from development and production. Phoenix integrates with OpenTelemetry and OpenInference instrumentation. Dynatrace completed its acquisition of Arize on October 1, 2026; Arize continues to provide its AI engineering products within Dynatrace.

AirMDR co-founder who leads security engineering. His published experience spans SIEM, incident detection and response, and security automation.

Published as Jeff Park on Arize AI’s current team page. This is the Arize Senior Software Engineer; a different person with the same name exists in Adex.

Published as Jim Groff on Arize AI’s current team page. This is the Arize Compliance Officer; a different person with the same name exists in Adex.

Published as Jing Wang on Arize AI’s current team page. This is the Arize Forward Deployed Engineer; a different person with the same name exists in Adex.

AirMDR co-founder and CEO with more than two decades of enterprise security and log-management experience, including ArcSight, Sumo Logic and LogicHub.

Published as Kunal Shah on Arize AI’s current team page. This is the Arize Staff Software Engineer; a different person with the same name exists in Adex.

Security marketing leader with prior roles at Check Point, Cisco, Seemplicity and CyCognito.

Luisa Wasilewski is a digital-health entrepreneur, investor, author and adviser. Andrej Steinberg’s original2023 Loop Ventures launch announcement identifies her as a venture partner. Her own current Pulsewave speaker biography identifies her as founder and CEO of Pulsewave and Future Health Academy, adviser to digital-health startups, a board member of Bitkom’s e-health working group and a member of DMEA2026 program leadership working on innovation, startups andAI. Earlier experience includes leading BrainwaveHub for more than fiveyears, building healthcare business models at HeartbeatLabs and consulting at Capgemini. Her Loop affiliation is explicitly qualified as publicly announced in2023 because a complete current fund roster is unavailable. Her authentic portrait is published on her own Pulsewave speaker page.

Andrej Steinberg is an early-stage technology and healthcare investor based in Berlin and a co-founder of Loop Ventures. His own2023 launch announcement identifies partners Michael Ströck and Bérénice Magistretti and a thesis focused on software for healthcare providers, payers and biopharma. Loop’s own September2026 website identifies Andrej as its lead contact, investing at inception and before, and presents selected investments across agenticAI, healthcare, biotechnology and enterprise software. In his earlier self-written2022 Auxilia article, he described his Calm/Storm Ventures investing role and gave founders advice on capital raising. That earlier role is historical; generic investor directories retaining it do not establish his current employer. The exact named NFX portrait is an authentic120px mirrored investor photograph; its original former-firm page is no longer accessible.

Bérénice Magistretti is a Swiss-Italian investor, writer and disability-accessibility advocate based in London. Her own biography describes her as a founding partner of Loop Ventures, an early-stage health and biotechnology fund, and her2023 launch announcement identifies Michael Ströck and Andrej Steinberg as co-founders. She previously covered Silicon Valley venture investment for VentureBeat and wrote for TechCrunch, WIRED UK, Vanity Fair and Forbes. Her publicly described work includes advocating for people with invisible disabilities and helping make startup ecosystems more accessible. The current loop.vc website does not publish a complete group roster, so her founding status is retained without claiming confirmed current employment. The original black-and-white portrait is from her own named About page.

Redwood Neuro Inc. is an Irvine, California biotechnology company developing ultrasensitive blood-based biomarker assays for Alzheimer's disease and other disease-detection applications. Its NIH-supported SiMoLiSA research aims to create an accessible multiplex assay for Alzheimer's biomarkers and validate it using clinical samples. NIH's National Institute on Aging awarded the company USD506,061 in September2025 for a PhaseI SBIR project led by Murat Baday with co-investigator Ahmet Ali Yanik. These published research affiliations are recorded without assuming executive titles or full-time employment. The company's website describes diagnostic performance ambitions, but clinical approval, validated15-year prediction, commercial effectiveness and undisclosed private financing are not independently established by the sources reviewed. No public executive directory or named private investors were found.

Electrical and computer engineering researcher, also published as Ali Yanik. UC Santa Cruz's own health and wellbeing research directory identifies him as an associate professor. NIH's2025 Redwood Neuro project identifies him as a co-principal investigator on ultrasensitive Alzheimer's biomarker research. This is a sourced research collaboration rather than an asserted executive or full-time corporate appointment.

Biophysics and computational-biology researcher and educator. Santa Clara University's own faculty biography describes a PhD from the University of Illinois Urbana-Champaign, research in bioengineering, medical imaging and data science, and diagnostic-technology entrepreneurship. NIH's2025 Redwood Neuro award identifies him as contact principal investigator; no Redwood CEO or founder title is inferred.

Colin Foster was identified as president of The Next Practices Group in its founder-authored2020 launch. His current biography identifies him as cofounder of The Next Practice agency, which joined Attivo in2025. His work connects brand, data and AI, including Accru iQ clinical-trial recruitment; previously social-media leadership at Novartis and Real Chemistry/W2O. Current NPG parent executive tenure is unverified.

Robert (Bob) V. Lardon was appointed chief strategy officer of The Next Practices Group inOctober2023, supporting network founders and business strategy. Previously strategy and investor relations at HARMAN, strategy leadership at Porter Novelli, and PwC shareholder-value consultancy leadership. His work includes artificial intelligence and immersive technologies. Current NPG tenure is unverified.

Bob Pearson founded and chaired The Next Practices Group, most recently confirmed by a2025 Healthcare Businesswomen’s Association biography. He has worked in healthcare and corporate communications at Dell, Novartis and Rhone-Poulenc Rorer, and helped develop GCI Health and Real Chemistry. A communications author and advisor working on AI adoption; current NPG executive roster remains unverified.

Michael (Mike) Gehb is a finance and operations executive and cofounder of The Next Practices Group. Its October2023 announcement names him founder and COO; his own contemporaneous colleague also names him CFO/COO. His current Symbionic Labs biography names him CFO and head of operations and confirms prior NPG cofounding. Previously finance leadership at Omnicom, Porter Novelli and Copithorne & Bellows; CPA. NPG employment end date is unknown.

The Next Practices Group (NPG) is a US corporate holding network founded in2020 to support founder-led communications, marketing, public-affairs, security and technology businesses. Its own2023 announcement describes capabilities in software, data science, analytics and artificial intelligence. Its AI relevance also includes a documented corporate investment in Autonomize AI’s May2023 healthcare-AI seed financing. Founder Bob Pearson’s July2020 announcement separately identifies a significant minority investment in FosterEquity Services. This profile represents the historical NPG corporate buyer, with The Next Practice agency, its client relationships and independent venture managers distinguished. Ownership has evolved: The Next Practice agency announced joining Attivo inMay2025; NSG announced its January9,2026 management purchase of majority ownership from NPG, with NPG retaining a minority interest; and Highwire acquired The Bliss Group inJanuary2026. Neither those agency transactions nor group revenues establish an NPG venture fund or company fundraising round. Both historical published NPG domains were unavailable on review, so a complete current central team and present legal registration are unverified. Leadership roles are individually qualified to their latest primary confirmation; subsidiaries’ current employees are not presented as current NPG staff.

Promaxo develops portable low-field magnetic resonance imaging and image-guided intervention technology for point-of-care urology. Its permanent-magnet MRI platform supports prostate biopsy guidance in outpatient settings. The company also develops AI-based tissue characterization and robotic needle guidance; those additional capabilities are described as under development and are not established as commercially cleared by the current company sources. The cleared MRI-guidance system uses pre-existing diagnostic MRI input; its own images are not intended for diagnostic use. The operating business launched in 2016 as Promaxo, Inc.; the current site identifies Promaxo Holdings, Inc., a holding issuer formed in 2024. It is based in Oakland, California. The current website names eight executive and board-secretary leaders, while 2026 securities filings identify additional board directors. Financing history includes MicroPort-backed Series A tranches, a Kineticos-backed Series B-1 tranche, a Huami/Zepp-led financing, direct investment by Fred Moll and an investment by Zynext Ventures. SEC offering targets and grant totals are distinguished from securities actually sold. Promaxo is separate from neuro42 despite sharing founder Amit Vohra.

Alek Nacev is published by Promaxo as Chief Science Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Alex Gonzalez is published by Promaxo as Senior Vice President in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Anil Dhingra is published by Promaxo as Executive Vice President in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Dushyant Chipalkatty is a director of Promaxo Holdings, Inc., as disclosed in its March 2026 SEC filing. His published Otomagnetics scientific-adviser biography describes founding PACK Pharmaceuticals in 2005 and earlier pharmaceutical operating and business-development experience at Morton Grove Pharmaceuticals and Carter-Wallace. He holds pharmacy degrees from Nagpur University and a master’s degree in pharmaceutical sciences from Rutgers. This pharmaceutical executive is distinct from similarly named robotics founders.

Michael Bartholomew is published by Promaxo as Secretary of the Board in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Ram Narayanan is published by Promaxo as Chief Technology Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Scott King is published by Promaxo as Chief Product Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Srirama Venkataraman is published by Promaxo as Chief Operating Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Tola Capital is a Seattle venture capital firm founded by enterprise software operators that invests globally in seed and early-stage AI and enterprise technology companies. It backs AI applications, infrastructure, responsible AI, security and governance technologies, and helps founders develop products, go-to-market strategies, customer connections, recruiting and financial operations.

Investor at Emergence Capital; previously worked at Qatalyst Partners and studied Computer Science at UCLA.

Kojo Osei is explicitly listed among US Tau Ventures' Investor Alumni. This is a historical affiliation rather than a claim of current employment; exact service dates are not published.

Kush Gupta is explicitly listed among US Tau Ventures' Investor Alumni. This is a historical affiliation rather than a claim of current employment; exact service dates are not published.

Lauren Maymar is explicitly listed among US Tau Ventures' Investor Alumni. This is a historical affiliation rather than a claim of current employment; exact service dates are not published.

Sonal Panda is publicly listed as an advisory partner of US Tau Ventures. This advisory affiliation is distinguished from the firm's core investment staff; appointment dates are not disclosed.

Ravi Varma, also identified in the firm's January 2026 newsletter as Ravi Varma Namboori, is a publicly listed venture partner of US Tau Ventures. The firm's own portrait and linked professional profile establish the same individual.

Larry Augustin is publicly listed as a venture partner of US Tau Ventures. This affiliation is distinguished from the firm's core investment staff; appointment dates are not disclosed.

Gary Ang is publicly listed as a venture partner of US Tau Ventures. This affiliation is distinguished from the firm's core investment staff; appointment dates are not disclosed.

Sharon Huang invests at US Tau Ventures. She previously worked on pharmaceutical strategy at Novartis and software for protein and genomic sequencing at Chan Zuckerberg Biohub. She studied computer science and epidemiology at Stanford and is continuing medical training at Mount Sinai. The current team page publishes Principal; the January 2026 newsletter calls her Vice President, without an assumed promotion date.

Insoo Chang invests in enterprise AI and financial technology at US Tau Ventures. Previously a senior vice president on Citigroup's strategic investment team, he co-founded the AI research-information platform NotedSource. He holds a Harvard MBA and Cornell economics degree. The current team page publishes Principal; the January 2026 newsletter calls him Vice President, with the discrepancy explicitly retained.

Sam Bogrov invests in digital health at US Tau Ventures. Previously he led financial operations at Pediatric Associates and worked in private equity at Investindustrial and Platinum Equity. He holds a Wharton MBA focused on healthcare management, a Vanderbilt bachelor's degree and a Claremont McKenna finance master's. The current team page publishes Principal; the January 2026 newsletter calls him Vice President, a source discrepancy retained rather than an assumed promotion date.

Sanjay Rao co-founded US Tau Ventures and focuses on enterprise software and automation. Previously he worked at Microsoft, McKinsey and Norwest and co-founded an automation startup. He holds MIT electrical engineering and computer science degrees and a Harvard MBA.

Amit Garg co-founded US Tau Ventures in 2019 and focuses on digital health and selected automation investments. His prior experience includes Google, Samsung NEXT and Norwest. He studied computer science and biomedical informatics at Stanford and earned an MBA at Harvard.

Loop Ventures is an early-stage investment brand launched publicly in2023 to back healthcare and biotechnology founders across healthcare delivery, life-sciences research and patient experience. Its own published mission focuses on turning health and bio into data-driven industries. The original named founding partners were Andrej Steinberg, Michael Ströck and Bérénice Magistretti, with Luisa Wasilewski announced as a venture partner; an additional biotech partner was not publicly named in the launch source. Autonomize AI’s own May2023 release identifies Loop as an actual investor in its closedUSD4M healthcare-AI seed financing. The current loop.vc website, published September2026, highlights Andrej Steinberg and selected investments spanning agentic healthcare AI, clinical knowledge, biotech, computer vision, AI infrastructure and enterprise automation. That personal-led selected-investment presentation does not establish that every listed investment was made by the original fund or that every founding partner remains employed. Earlier roles are time-qualified separately. A final fund close, current AUM and exact current legal manager have not been established in accessible primary sources; no reported homonym fund size or unrelated historical Málaga, Loup, SouthLoop, ClosedLoop or marketing-agency data is imported.

NOCD Inc. is a Chicago-based digital behavioral healthcare company specializing in obsessive-compulsive disorder and related conditions. Its licensed therapists deliver live video exposure and response prevention therapy, supported between sessions by messaging, symptom and ERP tools, and a patient community in the NOCD app. The company’s proprietary Noto platform uses AI-enabled tools for clinical documentation, scheduling, case management and therapist development; this supports clinician-delivered care rather than establishing autonomous diagnosis or a medication product. Founder Stephen Smith began designing the idea in 2014, and the current company story identifies its mission as beginning in 2015. NOCD publishes clinical outcomes research and serves patients across the United States and internationally where licensed. In January 2026, its investor 7wire Ventures reported NOCD’s acquisition of PTSD-care company Rebound Health and launch of Noto as a new parent-company platform; the NOCD brand and NOCD Inc. remain identified on the current service site.

Anil Vaitla is a co-founder and chief technology officer of NOCD. He helped develop the company’s early patient community and now works on technology supporting member education, therapy-session experiences, billing and other components of specialist OCD care.

Chris Novak is NOCD’s chief network operating officer. He focuses on expanding access to specialist OCD care and supporting the therapist network, including clinical training and the experience of therapists serving patients across urban and rural communities.

Erin Henkel is NOCD’s chief design officer. Her career spans healthcare and design, and her work focuses on creating a welcoming, accessible patient experience across NOCD’s digital services and treatment interactions.

Ilyas Patanam is a co-founder and chief growth officer of NOCD. He helped build its patient community and focuses on member-first growth, increasing understanding of OCD and connecting people with specialist treatment.

Jamie Feusner is NOCD’s chief medical officer, overseeing clinical outcomes, treatment development, research and payer and clinical partnerships. A psychiatrist and OCD researcher, he is also a University of Toronto psychiatry professor and senior scientist at the Centre for Addiction and Mental Health.

John Jurich is NOCD’s sales and chief revenue officer. He works on expanding access to specialist OCD care through payer coverage and commercial relationships, supporting the company’s technology-enabled clinical delivery model.

Larry Trusky is a co-founder and president of NOCD. His career spans healthcare technology, and he joined the founding team after its first patient-community product was developed. His work supports building technology and operations around direct patient care for people with obsessive-compulsive disorder.

Matt Thorne is chief financial officer of NOCD. His career has focused on the role of telehealth technology in healthcare. At NOCD, he supports a business delivering specialist treatment for obsessive-compulsive disorder through a combination of clinical care, technology and patient support.

Mia Nuñez is NOCD’s director of clinical integrity and director of continuing education. She helps select and assess new therapists, develops professional training and monitors treatment delivery and outcomes as part of its clinical leadership team.

Nicholas Farrell is NOCD’s director of clinical development and programming. He oversees the range of clinical services available through its therapist network and develops training and mentoring for clinicians treating OCD and related conditions.

Patrick McGrath is NOCD’s chief clinical officer. A licensed clinical psychologist with decades of OCD treatment experience, he oversees clinical protocols, therapist selection and training, and consultation on complex cases. He is the author of The OCD Answer Book and Don’t Try Harder, Try Different.

Stephen Smith is a co-founder and chief executive officer of NOCD. His experience seeking specialist care for obsessive-compulsive disorder inspired the company’s development. He began designing the idea in 2014, developed its app and patient community, and completed his degree at Pomona College.

Taylor Newendorp is NOCD’s network director of clinical training. A licensed clinical professional counselor, he oversees training for new and established therapists, including foundational exposure and response prevention instruction and advanced continuing education. He authored The Perfectionism Workbook.

Tracie Zinman-Ibrahim is NOCD’s chief compliance officer. She oversees risk and compliance policies, clinical auditing and therapist screening while also providing therapy in states where she is licensed. Her own experience receiving exposure and response prevention therapy informs her work treating OCD.

Karna D. Shinde is a personal angel investor and lawyer whose own KDS Global website describes a focus on medtech, deep technology and AR/VR. He publishes neuro42 and Promaxo among his investments. His investment amounts and round attribution are not disclosed on his own portfolio page; broad portfolio performance and regulatory claims are not independently adopted.

Stanford computer-science graduate; previously an AI investor at Bridgewater.

Joined as general partner in January 2025; previously an engineering and product executive at Meta and investor at Sequoia.

Previously an engineer at Neeva working on indexing, retrieval and language modeling, and a neuroscience researcher studying learning and epilepsy.

Jenny Ismert is an executive advisor to Valtruis and an independent healthcare consultant with more than two decades of Medicaid and Medicare experience. Before 2026 she held UnitedHealthcare executive roles in policy, innovation, technology and planning, most recently leading its Kansas Community Health Plan. She studied biology at the University of North Texas and earned an MBA in healthcare services from the University of Colorado.

Sam Deshpande is an executive advisor to Valtruis with over 30 years of experience in healthcare, consumer banking and consulting. He previously served as Humana chief information officer and chief risk officer, leading cloud, AI and data technology adoption. Earlier roles included Capital One, Accenture and Booz Allen Hamilton. His education includes an MBA from the University of Chicago and aerospace engineering degrees from Virginia Tech and IIT Kharagpur.

Paul Jansen is an Executive Advisor at Valtruis specializing in healthcare data and analytics, with extensive experience building and leading analytics teams that deliver actionable insights at scale. He is also a Co-Founder and Principal Consultant at Z2 Health Insights, a healthcare data and analytics consulting practice. Most recently, Paul led analytics at Tuva Health, developing analytics products on a widely adopted open-source healthcare analytics framework. Prior to that, he led value-based care analytics at Teladoc Health and built analytics functions at Bright Health, supporting Individual Marketplace and Medicare Advantage populations across multiple states. Earlier in his career, he held roles at Blue Cross and Blue Shield of Minnesota, the Minnesota Department of Health, and the Navy and Marine Corps Public Health Center. Paul holds a bachelor’s degree in Human Biology from Michigan State University and a Master of Public Health in Epidemiology from the University of Minnesota.

Dave Esler serves as an advisor to Valtruis specializing in human capital strategy, bringing more than 30 years of experience in Human Resource leadership roles across a range of industry sectors. Most recently, Dave served as Chief Administrative and Chief Human Resources Officer at Nashville-based Envision Healthcare. While with Envision, Dave was at the center of a transformative period of M&A activity that brought together a diverse group of healthcare services businesses that offer unique value propositions to clinicians, health systems, and payors. Prior to joining Envision, Dave served for eight years as Chief Human Resources Officer for Illinois-based US FoodsR, supporting more than 26,000 employees. Dave holds a master’s degree in Industrial and Labor Relations from the University of Wisconsin-Milwaukee, completed the Human Resource Executive Program at the University of Michigan, and has been designated a Certified Employee Benefits Specialist (CEBS) by the International Foundation of Employee Benefit Plans. Dave also earned a Bachelor of Science degree in Economics from the University of Wisconsin Oshkosh.

Andy Wong is a healthcare growth executive and operator with more than two decades of experience building, scaling, and transforming consumer and healthcare businesses. He has served in Chief Marketing Officer and Chief Growth Officer roles across high-growth healthcare organizations, with expertise spanning virtual and in-person care delivery, value-based care, women’s health, and employer and health plan markets. Andy has held leadership roles at some of healthcare’s leading consumer and technology-enabled companies, including Galileo, Herself Health, PlushCare, and Accolade. Across these organizations, he has built and led teams across growth, marketing, product management, and commercial strategy.  His track record includes scaling both direct-to-consumer and enterprise healthcare models while building differentiated brands that drive clinical outcomes and sustainable economics. Earlier in his career, Andy held roles at Procter & Gamble, The Boston Consulting Group, The Daily Beast, and Flywheel Sports. Andy holds an MBA from the University of Chicago Booth School of Business and a BA from the University of Michigan, Ann Arbor.

Miriam de Leon Diaz is Executive Assistant at Valtruis and coordinates logistics, communications and operations for the company’s leadership team. With more than a decade of experience in the healthcare and financial sectors, Miriam has served in administrative positions at OneOncology and CVS Health as well as J.P. Morgan Chase. Certified in Executive Administration, she is bilingual (Spanish) and has won awards for employee excellence at multiple companies. The Valtruis executive team is doing what they truly believe. They’re not just doing this as a ‘job.’ They are going to help make a change in healthcare, and things are going to get better. I admire that, and I'm proud to be a part of it. © 2026 Valtruis Companies | Team | News | Contact

Sarah is a Director of Finance and Administration at Valtruis. Before joining Valtruis, Sarah served as Manager of Corporate Accounting at American Industrial Partners and has nearly a decade of experience spanning private equity, asset management, and financial services. Sarah holds a Bachelor of Science in Accountancy with a Minor in Economics from DePaul University and studied international business at Corvinus University in Budapest.

Tracy Bahl is a Managing Director of Valtruis and an Operating Partner at WCAS, having joined in 2021 focusing on healthcare investments. He was formerly the President and Chief Executive Officer of OneOncology, a company dedicated to serving all those living with cancer through a network of leading community oncology practices across the U.S. Prior to OneOncology, Tracy served as Executive Vice President of Health Plans for CVS Health; Executive Chairman of Emdeon, an industry leading healthcare information and transaction services company; Special Advisor at General Atlantic; Chief Executive Officer of Uniprise, a UnitedHealth Group Company; and held various executive positions at CIGNA HealthCare. Tracy earned MBA degrees from Columbia University and the London Business School as well as a Bachelor of Arts degree from Gustavus Adolphus College. Tracy Bahl is publicly named in Despierta’s combined advisors and select limited partners roster. The source does not distinguish this individual’s advisory or LP capacity, identify a commitment amount, or supply a substantive biography; its generic image and placeholder biography are excluded. The affiliation is recorded with this explicit limitation.

Manav Sarkaria is a Vice President at Valtruis. Prior to joining the Valtruis team, Manav worked at private equity firm Clayton Dubilier & Rice, where he focused on investments in the healthcare sector. Earlier, he began his career as an Investment Banking Analyst at Morgan Stanley in the Mergers & Acquisitions Group. Manav holds a Bachelor of Science in Finance from Miami University.

Kathy Greer is a Director of Strategic Partnerships at Valtruis. Prior to joining, Kathy was an investor at Cerity Partners Ventures (formerly Touchdown Ventures), where she focused on healthcare venture investing in partnership with Fortune 500 companies. Earlier, she was a management consultant at ZS Associates and began her career at a healthcare technology startup. Kathy holds a Bachelor of Arts in Economics from the University of Michigan.

Karey Witty is Managing Director of Valtruis and an Operating Partner at WCAS, having joined in 2020 focusing on healthcare investments. He has over 30 years of experience across a range of senior executive roles in the healthcare industry. Prior to joining WCAS, Karey was the Chief Operating Officer at Envision Healthcare. Prior to Envision Healthcare, he has served as the CEO of Corizon Health Inc., EVP and CFO of naviHealth (a former WCAS XI portfolio company), CFO of HealthSpring, CFO of Valitas Health Services, and CFO of Centene Corp. Karey served as Chief Executive - Health Plan Business Unit at Centene after his time as CFO. Karey earned his Bachelor’s degree from Middle Tennessee State University.

Jess Bossmann is a Vice President at Valtruis. Prior to joining, Jess worked at private equity funds GTCR and Chicago Pacific Founders, where she focused on investments in the healthcare sector. Earlier, she worked in the Diversified Industrials Investment Banking group at J.P. Morgan. Jess holds a Bachelor of Business Administration in Finance from the University of Wisconsin-Madison.

Jack Tillotson is an Associate at Valtruis. Before joining Valtruis, Jack held a role in strategy and business development at agilon health, where he focused on fostering long-term partnerships with independent physician groups and health systems. Prior to that, he began his career at HealthScape Advisors, a management consulting firm, where he helped health plans, provider organizations, specialty health organizations, and investors navigate the evolving healthcare landscape. Jack earned his Bachelor of Business Administration in Accounting and Information Systems from the University of Wisconsin-Madison.

Isaac Ableman is an Associate at Valtruis. Prior to joining, Isaac worked at Baird Capital, where he focused on early stage and growth investments in the technology sector. Prior to that, he worked in the Industrials Investment Banking group at BMO Capital Markets. Isaac holds a Bachelor of Business Administration in Accounting and Finance from Ohio University’s Honors Business College.

Erin Murphy is an Executive Assistant at Valtruis, where she strives for operational excellence and executive success. Prior to joining Valtruis, Erin worked at various technology companies, including Platform Science, a telematics & fleet management company, and Pegasystems, a global CRM & BPM software company. Erin worked in various administrative roles during her time with Pegasystems and supported the Chief Executive Officer, Chief Financial Officer, and Chief Strategy Officer at Platform Science.

Claire McGee Sharma is an Associate at Valtruis, supporting Platform & Operations. Previously, Claire worked as an Innovation Consulting Associate at Healthbox and a Business Strategy Specialist at HIMSS. Prior to this, she held internship positions at Ohio Innovation Fund, a midwest venture capital fund, and Ariadne Labs, a joint center for health systems innovation at Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health. She is a Stanford University Innovation Fellow and is passionate about the potential for design thinking and technology to drive improvements in health care delivery. Claire Graduated Summa Cum Laude from Ohio University with a BS in Public Health and a BA in Spanish.

Corey Lenhoff is a Vice President at Valtruis. Corey brings experience as both a healthcare startup operator and management consultant; he joined the firm in 2021. Most recently, Corey worked at Pager, a digital health startup focused on care navigation, where he was responsible for strategic initiatives, partnerships and business development. He began his career at HealthScape Advisors, a management consulting firm dedicated to helping health plans, provider organizations, specialty health organizations and investors navigate the healthcare industry. Corey earned his Bachelor's degree from the University of Illinois Urbana-Champaign.

Callie Patel is Senior Vice President of Platform & Operations at Valtruis, bringing more than 10 years of experience partnering with healthcare stakeholders to drive positive transformation. Before joining the Valtruis team, she was a Director at Healthbox, a healthcare advisory firm that leading organizations trust with innovation, commercialization and digital strategy. Callie led engagements across Healthbox's consulting services, including overseeing all engagements focused on the drivers of health/health equity as well as the flagship Foundry Program, cultivating and assessing the viability, enterprise impact, and commercial potential of care team member-led new products and services. Prior to Healthbox, Callie managed healthcare engagements at Huron Consulting Group, spanning community-based hospitals, children's hospitals, academic medical centers, and regional/national delivery systems. Her focus comprised operational excellence, clinical transformation, technology implementations and change management. Callie holds a Bachelor of Science degree in Industrial and Systems Engineering from University of Wisconsin-Madison as well as an MBA from University of Chicago Booth School of Business.

Bo Shi is a Principal at Valtruis. Bo has over 10 years of experience partnering with entrepreneurs and executives in the technology, healthcare, and insurance industries. Most recently, Bo was a Vice President at the Blue Venture Fund and Sandbox Industries where he served on the board of directors for Abacus Insights, Alacura, and Ideal Option. Additionally, he was a board observer for Anzen, Care Connectors, Drips, First Dollar (acquired by Inspira Financial), HealthEdge, Limber Health (acquired by Net Health), and Solera Health. Earlier, Bo was an investor at Waud Capital Partners and Primus Capital, executing growth equity and buyout transactions for vertical software and healthcare companies. He began his career at L.E.K. Consulting. Bo earned his MBA with Honors from the University of Chicago Booth School of Business and his Bachelor of Arts in Economics from the University of Chicago.

Anna Haghgooie is a Managing Director of Valtruis and an Operating Partner at WCAS, having joined in 2021. Anna has over 15 years of experience partnering with entrepreneurs and operators to drive innovation in healthcare. Most recently, Anna was a Managing Director of the Blue Venture Fund and Sandbox Industries. She has previously served on the board of directors of Quilted Health, Somatus, ZeOmega, Contessa, Axial Healthcare, Origin, SonarMD, PWN Health, ExactCare, naviHealth (a WCAS XI former portfolio company), and Change Healthcare. Anna earned her MBA from the Booth School of Business at the University of Chicago and a Bachelor’s degree from the University of Michigan.

Anika Satish is an Associate at Valtruis. Prior to joining the team, she worked at Boston Consulting Group, where she focused on healthcare strategy across pharma, value-based care providers, and medtech. Anika holds a Bachelor of Science in Mechanical Engineering with a minor in Business from the University of Michigan.

Brian Anderson is published by Autonomize AI as Advisory Board Member. Physician and responsible-healthcare-AI leader, identified at appointment as CEO and co-founder of the Coalition for Health AI. His work spans healthcare interoperability, national health-technology policy and consensus frameworks for AI safety, validation and effectiveness.

Bill Fandrich is published by Autonomize AI as Advisory Board Member. Healthcare and financial-services executive with four decades of published experience in enterprise transformation, operations, analytics and artificial intelligence. Advises on scaling AI-enabled operating models and business modernization.

Keith Reynolds is published by Autonomize AI as Advisory Board Member. Digital-health and payer-industry executive, described at appointment as Welldoc ChiefOperatingOfficer and a former CVSHealth executive. Brings experience commercializing AI-enabled healthcare solutions and payer innovation to Autonomize’s advisory board.

Anthony Alvarez is Advisor at Autonomize AI, an Austin-based enterprise healthcare software company developing specialized AI agents and orchestration tools for clinical and operational workflows.

Pritesh Gandhi is published by Autonomize AI as Medical Advisor. Physician and public-health-qualified medical adviser published in the current directory and the2025 advisory-board announcement. This is an expert advisory affiliation rather than employment as company ChiefMedicalOfficer or an inferred personal investment.

Michele Paige is published by Autonomize AI as Advisor, Growth Advisory Board. Pharmacy-benefit-management and pharmacy-operations leader with earlier ElevanceHealth CarelonRx product and digital-strategy experience, including specialty-pharmacy and affordability initiatives. Advises Autonomize growth and pharmacy-linked AI workflows.

Tamara Elias is published by Autonomize AI as Advisor, Growth Advisory Board. Physician executive and former private-equity partner with nearly a decade of investing experience. Published earlier operating and partnership roles span Microsoft/Nuance, Merck, Aetna, BectonDickinson and McKinsey; advises growth across healthcare delivery, pharma and enterprise technology.

Anthony Nguyen is published by Autonomize AI as Chair, Medical Advisory Board (adviser-directory affiliation). Physician and MBA-qualified MedicalAdvisoryBoard chair in the current advisory directory. Its caption additionally says ChiefMedicalOfficer, but SandhyaGardner’s explicitApril23,2026 appointment establishes the current executiveCMO; that potentially older advisor caption is retained only as a source-qualified attribution, not a second asserted executive appointment.

Joan Harvey is published by Autonomize AI as Chair, Growth Advisory Board. Chairs Autonomize’s GrowthAdvisoryBoard, which convenes healthcare industry leaders to guide enterprise expansion and strategic partnerships. This advisory role is distinct from a company board-director appointment and a personal investment ticket.

Mike Longacre is published by Autonomize AI as Head of Transformation. Healthcare transformation executive with more than20 years leading modernization across health plans, pharmacy benefit managers and technology companies. Previously a partner in PwC’s HealthTransformation practice, with earlier ConnectureDRX and UnitedHealthcare leadership; supports enterprise adoption, governance and operating-model change.

Shiv Mallya is Head of Delivery at Autonomize AI, an Austin-based enterprise healthcare software company developing specialized AI agents and orchestration tools for clinical and operational workflows.

Prajna Kandarpa is Chief Architect at Autonomize AI, an Austin-based enterprise healthcare software company developing specialized AI agents and orchestration tools for clinical and operational workflows.

Aizen Therapeutics is an AI-native biotechnology company developing oral peptide medicines for chronic immune disorders. Its DaX platform uses computational protein design to create peptides with non-canonical amino acids, including D-amino acids that form mirror-image peptides. The company is advancing gut-restricted and systemic oral biologics and collaborates with biopharmaceutical partners on peptide discovery, delivery and signaling challenges. Its technology originated in David Van Valen’s laboratory at Caltech, and the company is based in San Diego.

Synthesize Bio develops generative genomics foundation models that predict human tissue and cell responses to drugs, diseases and experimental conditions. Its GEM models generate bulk and single-cell RNA-sequencing data from natural-language experiment descriptions, supporting virtual patient cohorts, biomarker research, safety analysis and clinical trial design. The company works with biotech and pharmaceutical teams to extend limited datasets and test development decisions before expensive studies. Its outputs support research and internal decision-making; the company states that they cannot currently serve as primary evidence in regulatory submissions.

Caltech faculty scientist whose laboratory developed the DaX peptide-design platform from which Aizen spun out.

Co-founder and current co-CEO; Fred Hutchinson Cancer Center chief data officer and RNA informatics researcher. Academic title is distinct from his company role.

University of Utah School of Medicine scientist and D-peptide therapeutics specialist, independently identified by Madrona’s Aizen investment announcement.

Also published as Rob Bradley in the issuer’s financing release and Madrona announcement. Fred Hutchinson Cancer Center researcher and translational data science leader; academic position is distinct from his Synthesize co-CEO role.

Published board advisor, distinct from a board director or employee.

Published as observer in Aizen’s Board Members section, not a voting director or employee.

Gina Collins is published by Autonomize AI as Chief Regulatory Officer. Healthcare regulatory and operational executive with more than20 years of experience. Former office director at FDA’s Center for Devices and Radiological Health and earlier Cigna operational, risk and compliance leader; directs Autonomize regulatory strategy, compliance and enterprise risk management.

Jennifer Rouse is published by Autonomize AI as VP Marketing. Healthcare marketing executive with more than20 years of B2B experience. Former worldwide healthcare-marketing leader at AWS, with earlier IBM, Cisco and Forrester leadership/advisory work across cloud, cybersecurity, compliance and enterprise AI.

Scott Brennan is published by Autonomize AI as Head of Growth. Healthcare growth executive with more than15 years of go-to-market experience. Previously SVP of BusinessDevelopment at TurningPointHealthcareSolutions, supporting value-based musculoskeletal and cardiovascular care arrangements, and helped scale an earlier healthcare company through acquisition.

Ujjwal Rajbhandari is published by Autonomize AI as VP Solutions & Delivery Engineering. AI-infrastructure and cloud-strategy executive with earlier Google and Dell leadership. Previously a startup co-founder and CTO developing hybrid-cloud GPU-as-a-Service infrastructure. September2025 appointment was Head of Solutions; current directory title is VP Solutions and DeliveryEngineering, whose exact promotion date is undisclosed.

Peter Kirby is a venture partner at ATX Venture Partners. His published biography describes early Bitcoin hardware and blockchain-company entrepreneurship, including Factom, and biochemistry and business study.

Sophia Onat is publicly identified as an ATX Venture Partners team member by the firm founder’s welcome announcement and her own professional profile. A specific current job title and individual manager-published portrait have not been verified.

David Godwin is a venture partner at ATX Venture Partners. His manager biography describes technology entrepreneurship and cofounding Slingshot Aerospace; an older external CEO title is not asserted as a verified current appointment.

Jeff Gray is a venture partner at ATX Venture Partners. His published biography describes infrastructure, cloud and cybersecurity leadership and technology consulting.

Michael Flory is a venture partner at ATX Venture Partners. His published biography describes consulting and investment activity through MRFH, and prior operating experience at Rovia and CarTrawler.

Tony Capasso is a venture partner at ATX Venture Partners. His published biography describes revenue leadership at YouEarnedIt/HighGround, ShipEngine, Bazaarvoice and Civitas Learning; these are career references rather than independently verified current outside appointments.

Dave Ritter is a venture partner at ATX Venture Partners. His published biography describes former McKinsey partnership and U.S. Army leadership experience and operations-research study.

Sandhya Gardner is published by Autonomize AI as Chief Medical Officer. Board-certified obstetrician-gynecologist and ACOG fellow with more than25 years spanning clinical practice and healthcare technology. Earlier HealthEdge ClinicalSaaS GeneralManager/CMO, Wellframe CMO and Relias/AdvancedPracticeStrategies leadership. Leads clinical strategy, AI validation and safety, and enterprise adoption.

Laksh Krishnamurthy is published by Autonomize AI as CTO. Technology executive with more than thirty years of experience in platform engineering, AI and advanced analytics. Earlier leadership at Tecnotree and CognitiveScale and technical work at IBM; the firm describes him as an IBM Master Inventor with55 patent filings and an operations-research/computer-applications master’s degree.

Spencer Lucas is chief financial officer of ATX Venture Partners, as published in the current own directory. No expanded biography is published in his current website panel.

Kris Nair is published by Autonomize AI as COO & Co-Founder. Co-founder of Autonomize in2022 with Ganesh Padmanabhan. As COO he represents the company’s operational development of healthcare intelligence and agentic workflows, including its2026 claims payment-integrity application. The native directory does not disclose an extended earlier career biography.

Emerson Miller is a principal at ATX Venture Partners. His manager biography describes entrepreneurial, racing-business operating and technical data-analysis experience. The firm announced his promotion effective January1,2026.

Ganesh Padmanabhan is published by Autonomize AI as CEO & Co-Founder. Enterprise AI and cloud executive with more than twenty years of experience. Former Dell Technologies executive who co-founded Autonomize with Kris Nair in2022 to build governed AI-native healthcare workflows.

Kevin Fiur is a partner at ATX Venture Partners. His manager biography describes operating, legal and transaction experience at iFLY and Baker Botts, with degrees from the University of Texas at Austin and Acton School of Business.

Danielle Allen, also legally Danielle Weiss Allen, is a partner and cofounder of ATX Venture Partners and head of ATX Global Co-Invest. Her manager biography describes institutional finance experience at JPMorgan, Nomura and Millennium; she attended Tulane and earned an MBA from Zicklin.

ATX Venture Partners is the Austin-based investment brand of ATX Seed Management, LLC, CRD289522, formerly known as ATX Seed Ventures. Its current strategy targets early-stage applied AI across North American defense and space, industrial and physical operations, healthcare and enterprise software, and financial infrastructure. It emphasizes leading or co-leading seed and Series A financings and supporting founders with operator experience. The current website publishes five core investment/finance members and six venture partners; a founder announcement additionally confirms team member Sophia Onat, whose specific title and individual headshot are not published on the website. Its disclosed AI and hardware portfolio includes Autonomize AI, Pensa, Protopia AI, Slingshot Aerospace and MacroFab. Current SEC reporting distinguishes ten actual flagship, parallel and co-investment vehicles; their book values, offering targets and partial securities sales are not presented as final fund closes.

Julian Spears is Head of Neurosurgery at St. Michael’s Hospital, Unity Health Toronto. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Adnan Siddiqui is Vice-Chairman and Professor of Neurosurgery at University at Buffalo. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Michael Schulder is Professor and Vice Chairman of Neurosurgery at Hofstra/Northwell. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Todd Patrick is Chief of Neurosurgery at Christus Trinity Mother Frances Health System. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Debraj Mukherjee is Associate Professor and Assistant Residency Program Director of Neurosurgery at Johns Hopkins. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Brian Jankowitz is Chief of Neurosurgery at JFK University Medical Center, New Jersey. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Elad I. Levy is Professor and Chair of University at Buffalo Neurosurgery. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

G. Michael Lemole Jr. is Skull-base and cranial neurosurgeon at Jefferson Abington Hospital and professor at Thomas Jefferson University. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Hakan Emmez is Professor of Neurosurgery at Güven Hospital, Ankara. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.

Daniel J. Wolterman has served on Hyperfine’s board since December 2021 and is its current chairman. He leads Wolterman Consulting, previously led Memorial Hermann Health System and briefly ColubrisMX and X-Cath, and serves on the Globus Medical board. He studied business at Cincinnati and healthcare administration at Xavier.

Jonathan M. Rothberg, PhD, founded legacy Hyperfine in 2014 and Liminal Sciences in 2018, and served as legacy Hyperfine CEO through 2021. He founded the 4Catalyzer incubator and biotechnology businesses including Butterfly Network and Quantum-Si. His scientific work helped commercialize high-speed DNA sequencing. He holds biology degrees from Yale and chemical engineering from Carnegie Mellon. Jonathan M. Rothberg founded the operating predecessor of Quantum-Si in2013. Current issuer governance confirms he remains a director; his chairmanship ended May2024 and interim chief executive role ended October2022.

Ruth Fattori has served on the public Hyperfine board since December 2021 and joined the legacy company’s board in August 2021. She is an independent consultant with earlier executive HR roles at PepsiCo, MetLife and Motorola and advisory experience at BCG. She holds a mechanical-engineering degree from Cornell. Ruth Fattori has served on the Quantum-Si public board since June2021 and predecessor board since March2021. Her issuer biography describes Pecksland Partners managing director and Boston Consulting Group senior advisor roles, former PepsiCo CHRO, MetLife and Motorola leadership, and a Cornell mechanical-engineering degree.

John Dahldorf has served on Hyperfine’s board since its December 2021 business combination. He is CFO of Q’Apel Medical and formerly held CFO positions at Adagio Medical, SCN BestCo and Acutus Medical. He holds finance and MBA degrees from Western Illinois University.

Leslie Grab, PhD, is Hyperfine general counsel. She previously led legal and people functions at BigHat Biosciences, intellectual property and privacy at Personalis, and patent and employment counsel work at Verily. She holds a JD from UNC and a biochemistry PhD from Wake Forest.

Rafael O’Halloran, PhD, leads technology at Hyperfine and developed its AI-driven MRI image pipeline. His expertise includes MRI physics, sequence development and image reconstruction. He previously researched diffusion imaging and neuromodulation at Mount Sinai and Stanford, and studied medical physics at Wisconsin and physics at Louisiana State.

Eric Willis leads Hyperfine international business. His earlier experience includes general management at Eargo, CEO and COO positions at early-stage companies, and leadership roles at Boston Scientific, Guidant and FoxHollow. He holds mechanical-engineering degrees from Stanford and UC Santa Barbara.

Todd Finch leads US sales at Hyperfine. He previously held commercial roles at Intuitive Surgical, VitalConnect, Medtronic and Abbott. His experience centers on building medical-technology sales teams; he studied English and history at Appalachian State University.

Chi Nguyen leads Hyperfine office and community business. Her experience covers medical-device strategy, marketing and market development, including NeuroPace, Spinal Modulation, Acclarent/Johnson & Johnson, Guidant and Bain. She holds an MBA from Stanford and a BA from Yale.

Rafael Donnay leads Hyperfine hospital business. Previously he was senior vice president of product and reimbursement at Ceribell, serving on its leadership team from Series A through IPO, and held marketing leadership roles at Philips, Stryker Neurovascular and Medtronic. He studied at Wharton, Stanford and Columbia.

Edmond Knopp, MD, is Hyperfine chief medical officer. He has three decades of radiology, neuroradiology and MRI experience, including faculty and director roles at NYU School of Medicine. He studied biology at Emory and medicine at SUNY Downstate, and has served as an American Board of Radiology examiner.

Rob Fasciano, PhD, leads regulatory and quality functions at Hyperfine. His twenty-five years in medical devices and diagnostics include R&D, quality and regulatory leadership at Abiomed, Johnson & Johnson, Orchestra BioMed and Impulse Dynamics. He holds degrees from Johns Hopkins, Purdue, Boston University and Dartmouth.

Tom Teisseyre, PhD, is Hyperfine chief operating officer. A founding Verily team member, he previously headed surgical and implantable devices and worked at Google, Abbott Medical Optics, Proximie and OptiMedica. His expertise includes medical imaging and surgical technology. He studied bioengineering at Berkeley/UCSF and biomedical engineering at Georgia Tech.

Hyperfine, Inc. (Nasdaq: HYPR) is a Guilford, Connecticut medical-technology company developing portable, ultra-low-field MRI and AI image reconstruction for brain imaging. Its Swoop system is FDA cleared for producing images of the head at professional points of care where a full diagnostic examination is not clinically practical; its Optive AI software improves image reconstruction. The current business serves hospitals, neurology offices and selected international markets. Founded by Jonathan M. Rothberg in 2014 within 4Catalyzer, the legacy operating business became Hyperfine Operations, Inc. when it and Liminal Sciences combined with HealthCor Catalio Acquisition Corp. on December 22, 2021. The former SPAC renamed itself Hyperfine, Inc.; Liminal Operations became another subsidiary. This profile represents the continuing Hyperfine operating business and its public parent, with historical issuer scope identified in each financing source. Current named leadership includes eleven executives, five board members with one overlap, and nine neurosurgery advisers appointed in June 2026. Historical private financings, completed public-company merger proceeds, executed market share sales, restricted research grants and funded debt are separately qualified.

Brett Hale leads administrative and financial operations at Hyperfine. His earlier CFO roles included Bigfoot Biomedical, Cardiokinetix, Vibrynt and Concentric Medical; he also worked at Emphasys, Guidant and PwC. He holds accounting and finance degrees from Indiana University and an inactive CPA qualification.

Maria Sainz is president, CEO and a director of Hyperfine. She previously led AEGEA Medical, Cardiokinetix and Concentric Medical and has thirty years of medical-technology commercial and executive experience. She studied languages at Complutense University and international management at Thunderbird.

MRI scientist whose published2022 neuro42 interview describes pulse-sequence development, image reconstruction and processing, technical experiments and regulatory-submission support. Historical2022 employment is explicitly qualified; no departure date or current operating appointment is inferred.

Software engineer whose published2022 neuro42 interview describes designing and testing end-user applications, troubleshooting and maintaining software systems. Historical2022 employment is explicitly qualified; no departure date or current operating appointment is inferred.

MRI scientist whose published2022 neuro42 interview describes developing MRI reconstruction pipelines and working with RF, gradient and systems engineers on signal and image processing. Historical2022 employment is explicitly qualified; no departure date or current operating appointment is inferred.

Electrical engineer whose published2022 neuro42 interview describes designing and testing printed circuit boards and troubleshooting hardware. Historical2022 employment is explicitly qualified; no departure date or current operating appointment is inferred.

Radiofrequency engineer whose published2022 neuro42 interview describes constructing MRI RF coils and contributing as an early member of the engineering team. Historical2022 employment is explicitly qualified; no departure date or current operating appointment is inferred.

MRI scientist whose published2022 neuro42 interview describes customized pulse sequences and advanced image-reconstruction algorithms. Official NIH2026 projectU44NS136026 identifies Xiaowei Zou as a co-principal investigator at neuro42; this establishes a current research affiliation without asserting that the older operating title remains current. Historical2022 employment is explicitly qualified; no departure date or current operating appointment is inferred.

Chris Shonk is published by Autonomize AI as Board Observer. This is a governance affiliation with the Austin-based healthcare agentic-AI company, which develops orchestration software for clinical and administrative workflows. The own director/observer directory does not disclose an appointment date or a personal investment ticket; institutional financing is recorded separately. Chris Shonk is a partner and cofounder of ATX Venture Partners. The manager biography describes entrepreneurial and investment experience including Virtus Financial Group, EZ Money Pawn and Sneaky Games, and degrees from Campbell University and the Acton School of Business.

Mike Spadafore is published by Atropos Health as board member. Managing Director of Valtruis. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket. Existing separately sourced biography: Mike Spadafore is a Managing Director of Valtruis and an Operating Partner at WCAS, having joined in 2024. Mike has more than 15 years of experience working closely with entrepreneurs and executives in the healthcare and technology markets. Most recently, Mike was a Managing Director of the Blue Venture Fund and Sandbox Industries. He has previously served on the board of directors of Nest Health, Fort Health, First Dollar, Smart Data Solutions, Abacus Insights, Workit Health, WiderCircle, Prove, ID Experts (acquired by ZFOX), Wellframe (acquired by Healthedge), Physera (acquired by Omada Health), and Patientco (acquired by Waystar). While at Sandbox, he also founded and built Sandbox Advisors, a strategy and transaction consulting firm serving healthcare clients. Prior to that, he was a management consultant at PwC and Diamond Management and Strategy Consulting. Mike earned his Bachelors of Business Administration from the University of Michigan. Existing separately sourced biography: Mike Spadafore is published by Autonomize AI as Board Member. This is a governance affiliation with the Austin-based healthcare agentic-AI company, which develops orchestration software for clinical and administrative workflows. The own director/observer directory does not disclose an appointment date or a personal investment ticket; institutional financing is recorded separately.

Skip Fleshman is published by Autonomize AI as Board Director. This is a governance affiliation with the Austin-based healthcare agentic-AI company, which develops orchestration software for clinical and administrative workflows. The own director/observer directory does not disclose an appointment date or a personal investment ticket; institutional financing is recorded separately. David G. “Skip” Fleshman is a managing member of Asset Management Ventures, LLC, identified in its March 2026 SEC filing. The firm’s own team biography brands him as Skip Fleshman and Partner. His legal name is David G. Fleshman; this is the same institutional investment manager and Autonomize AI director.

Tau Ventures is a US venture capital firm founded in late 2019 by Amit Garg and Sanjay Rao, investing in early-stage companies applying artificial intelligence to healthcare, enterprise software and automation. Based in Palo Alto, with a presence in New York and San Francisco, it primarily backs seed-stage startups and selectively supports later financing. Its published portfolio includes healthcare AI companies Autonomize AI, Assort Health, Alaffia Health and Infinitus, enterprise AI developer Labelbox, and robotics company Chef Robotics. The team combines operating, software, biomedical-informatics and investment experience; venture partners and an advisory partner are distinguished from core investment staff, and investor alumni are identified as historical affiliations. Its broad external advisor directory represents a separate professional network. The manager’s January 2026 newsletter reported more than USD93 million in assets under management across its earlier fund and SPV platform; this is not a single fund closing amount. An August 2026 newsletter confirms the first close of Tau Ventures Fund III, without disclosing its size or exact closing day. The US firm at tauventures.com is separate from Tel Aviv’s TAU Ventures at tauventures.co.il, whose existing record is preserved. The manager’s exact legal identity is Tau Ventures, LLC (US SEC exempt reporting adviser CRD306230); it is not a registered investment adviser. Official fund disclosures and direct founder testimony identify a USD17 million fully raised Fund I, a USD26.3 million Opportunity Fund I and a USD40.5 million closed Fund II. Exact closing days are undisclosed. Separately identified legal vehicles include Tau Ventures SPV DCAP, LLC and the Fund III main and QP partnerships. Current gross asset values, planned closes and platform AUM are not substituted for fund closing capital.

Autonomize, Inc., operating as Autonomize AI, is an Austin, Texas enterprise healthcare AI company founded in 2022 by Ganesh Padmanabhan and Kris Nair. Its intelligence platform combines specialized AI agents, workflow orchestration, contextualized clinical and policy evidence, and human review to support health plans, providers and life-science organizations. Applications include prior authorization, utilization and care management, appeals, claims, contracts, pharmacy workflows and payment integrity. Its Genie AI product lets healthcare professionals design and refine governed agents and workflows through natural-language interaction. The company raised USD 4 million in seed funding in May 2023 and USD 28 million in Series A funding in June 2025, totalling USD 32 million across those two disclosed rounds.

Dtwo builds a security control plane for enterprises using AI agents and the Model Context Protocol. Its managed gateway sits between agents and business tools, applies identity-aware and context-aware access policies, and can allow, block or redact tool calls and returned data. It centralises permissions, credentials and audit trails across agent workflows, helping businesses control which systems an agent can reach and which actions it can take. The platform integrates with enterprise identity systems and supports policies expressed in natural language and enforced as code.

FeatureByte develops an AI data-science agent that turns enterprise data and business questions into predictive models, analytics and operational decisions. Its platform automates data preparation, feature engineering, model development and deployment, while providing reusable features, production data pipelines and governance for predictive AI. It is designed to help organisations build and operate models without manually assembling every stage of the data-science workflow. Founded in 2022, the business was acquired by ServiceNow in September 2026 and now presents itself as FeatureByte by ServiceNow.

Publishes as Chris Price on the company blog.

Security and SaaS entrepreneur who built Cisco firewall-management software and architected Aveksa identity-management software. Also co-founded Genie Life Sciences.

DevOps and AWS professional whose public profile lists DTwo AI; exact company title is not public.

Previously led R&D at DataRobot, including teams developing time-series and data-management capabilities.

Software engineer and UI designer based in Montevideo. His public profile lists DTwo AI but does not expose his exact company title.

Technology commercialisation professional focused on AI, controls, data and regulated operations; founded Root Health during his MBA.

Analytics and commercial leader who previously helped scale DataRobot and develop its services-led go-to-market strategy.

Kaggle Grandmaster and former founding-team member at DataRobot, where he led professional services.

Former DataRobot chief data scientist with an actuarial background; a Kaggle Grandmaster who has held its top rank.

John Snodgrass is an associate at Piper Heartland Healthcare Capital based in Minneapolis. He joined after the flagship fund had its first close in 2021. He holds an economics degree from Colgate University.

Trent Holland is a vice president at Piper Heartland Healthcare Capital based in Minneapolis. He joined Piper Sandler in 2019 and previously worked in healthcare investment banking, covering biopharmaceutical companies and public and private capital raises, partnerships and M&A. He holds a finance degree from the University of Colorado Denver.

Ahmad El Naggar is a director at Piper Heartland Healthcare Capital focused on biopharma and medical-technology investing. His portfolio work includes AdvanCell, Alentis Therapeutics and Avalyn Pharma. He previously worked in Piper Sandler healthcare investment banking and at Viscogliosi Bros. He served as a U.S. naval officer and studied at Duke, Johns Hopkins and Oxford.

Matt Hemsley is CEO of Piper Heartland Healthcare Capital, manages its healthcare crossover strategy and chairs the Heartland Summit. He joined Piper Sandler in 2010 after working at McKinsey and Goldman Sachs. His healthcare transaction experience spans medical devices, biopharma and healthcare technology. He studied at Georgetown, Oxford and Stanford.

Earthmover develops cloud data infrastructure for scientific datasets and AI models of the physical world. Its open-source Icechunk engine stores multidimensional tensors and arrays, while Arraylake provides shared catalogs, versioning, permissions and governance for scientific data in customers’ cloud storage. Its compute and delivery services support analysis and access close to the data, and its marketplace connects users with analysis-ready datasets. The platform serves weather, climate, ocean, Earth observation and other scientific workflows, including bioimaging and omics, helping research and commercial teams work with large datasets without building bespoke file-based pipelines. Earthmover is a public benefit corporation founded by climate scientists and open-source developers.

Hidden Level develops passive radar and radio-frequency sensing technology that detects, locates and tracks drones, aircraft and other aerial threats without actively transmitting signals. Its distributed hardware sensors, software and data services turn activity in the electromagnetic spectrum into real-time airspace and spectrum awareness. Defense, critical infrastructure and public safety operators use the technology to monitor threats while limiting the exposure of their own sensing equipment. Founded in 2018 in Syracuse, the company also manufactures and scales its sensing systems for government and commercial deployments.

Operations executive overseeing quality, purchasing, hardware delivery and manufacturing growth.

Former senior naval officer and aviator with experience in military operations, strategy, government relations and communications.

Product engineering leader and systems architect overseeing Arraylake development.

Former U.S. Navy leader and aviator working on international engagement, security cooperation and defense business development.

Oceanographer and open-source maintainer working on Icechunk, Flux and compute; previously at NCAR and creator of flox.

Hidden Level co-founder, explicitly published by investor Costanoa. The current issuer leadership directory names Tim Graham as chief technical officer, so no current CTO appointment is asserted for Dominicos.

Microscopy and scientific software developer supporting Xarray’s imaging and omics applications through Chan Zuckerberg Initiative funding.

Legal executive with experience in government, startups, compliance and scaling defense technology companies.

Executive and co-founder working on RF technologies for defense, aviation and intelligence applications.

Climate scientist and engineer, previously at NCAR and CarbonPlan; University of Washington PhD, Pangeo co-founder and Xarray/Zarr developer.

Oceanographer and research software engineer helping climate teams move data and analysis to the cloud.

Products and programs leader experienced in hardware and software delivery across commercial, federal and defense customers.

Engineer developing Arraylake, with earlier machine learning and Earth observation infrastructure experience at Maxar, Arturo and Pachama.

Software engineer working on Icechunk and Arraylake, with a UC Davis computer science PhD and experience in genomic data tools.

Operations executive formerly leading products and developer platforms at Heroku, Salesforce, dbt Labs and Armory.

Software and ocean engineer building product features across the platform.

HR leader responsible for recruiting, talent development, performance management and organizational design.

CPA and finance executive experienced in accounting, operations and government and commercial business environments.

Oceanographer and climate scientist, formerly a Columbia professor; MIT PhD and Pangeo co-founder, now leading scientific data infrastructure development.

Infrastructure engineer scaling backend deployment, with prior distributed computing work at Coiled.

Engineering leader and principal author of Icechunk, originally trained in mathematical physics.

Operations leader coordinating company functions including marketing and financial administration.

Sensor technology and engineering leader with more than twenty years of experience and patents in radar and sensing.

Customer-facing engineer and Xarray contributor helping scientific teams adopt cloud-native data workflows; original author of DataTree and VirtualiZarr.

Ge Li is publicly named by Swinburne in its university innovation/commercialisation support directory as Marketing and Communications Coordinator. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Jenny Bevis is publicly named by Swinburne in its university innovation/commercialisation support directory as Senior Coordinator, Innovation Programs (Commercial). This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Sarah Barter is publicly named by Swinburne in its university innovation/commercialisation support directory as Senior Coordinator, Innovation Programs. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Anu Mavilakandy is publicly named by Swinburne in its university innovation/commercialisation support directory as Manager, Intellectual Property Commercialisation. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company. The live directory marks this person on maternity leave.

Michelle Xu is publicly named by Swinburne in its university innovation/commercialisation support directory as Senior Partnerships and Ecosystem Manager. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Milana Momcilovic is publicly named by Swinburne in its university innovation/commercialisation support directory as Innovation Services Manager. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.

Alex Hadley is publicly named by Swinburne in its university innovation/commercialisation support directory as Manager, Intellectual Property Commercialisation. This is an affiliated university support role, not a verified direct employment or director appointment at the legal investment company.